Treatment with anti-kir3dl2 agents

Abstract

This disclosure relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.

1 - 41 . (canceled) 
     
     
         42 . A method of treating a T cell malignancy with tissue manifestation in both individuals having blood involvement and in individuals lacking blood involvement, the method comprising administering to an individual having a T cell malignancy an agent that binds a KIR3DL2 polypeptide and is capable of causing effector cell-mediated lysis of a KIR3DL2-expressing cell, for at least one administration cycle in which the agent is administered at least twice in an amount that maintains a concentration in blood of at least the EC 60  for NK lytic capacity, between two successive administrations of the agent, wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide and is administered in an amount of 10 mg/kg body weight, and wherein the treatment regimen comprises:
 an induction period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one administration per week, and   a treatment period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one or two administrations per month, and   wherein the agent is an antibody comprising: a heavy chain CDR 1, 2 and 3 (HCDR1, HCDR2, HCDR3) comprising SEQ ID NO: 2 (HCDR1), SEQ ID NO: 3 (HCDR2) and SEQ ID NO: 4 (HCDR3) respectively, and a light chain CDR 1, 2 and 3 (LCDR1, LCDR2, LCDR3) comprising SEQ ID NO: 5 (LCDR1), 6 (LCDR2) and 7 (LCDR3), respectively.   
     
     
         43 . The method of  claim 42 , wherein the treatment is effective in both individuals having high blood tumor burden and in individuals having low blood tumor burden. 
     
     
         44 . The method of  claim 42 , wherein treatment is used as first-line treatment. 
     
     
         45 . The method of  claim 42 , wherein the individual has not received bone marrow transplantation or hematopoietic stem cell transplantation. 
     
     
         46 . The method of  claim 42 , wherein the agent is administered intravenously. 
     
     
         47 . The method of  claim 42 , wherein the T cell malignancy with tissue manifestation is a CTCL. 
     
     
         48 . The method of  claim 47 , wherein the CTCL is an indolent CTCL. 
     
     
         49 . The method of  claim 42 , wherein the treatment or method is used for the treatment or prevention of T cell proliferative disease in individuals substantially lacking detectable KIR3DL2-expressing malignant cells in circulation. 
     
     
         50 . The method of  claim 42 , wherein the treatment or method is used for the treatment of T cell proliferative disease in individuals having high blood tumor burden, optionally B2 peripheral blood involvement. 
     
     
         51 . The method of  claim 42 , wherein the same administration regimen is used for the treatment or prevention of T cell proliferative disease in individuals having stage 2 or 3 Mycosis fungoides. 
     
     
         52 . The method of  claim 42 , wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide and comprises an Fc domain of human IgG isotype that binds to a human CD16 polypeptide. 
     
     
         53 . The method of  claim 42 , wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide and is capable of causing an increase of cell surface KIR3DL2 polypeptide available for binding by an anti-KIR3DL2 antibody. 
     
     
         54 . The method of  claim 42 , wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide, comprising an Fc region derived from a human IgG1 isotype, characterized by an EC 50  in a  51 Cr-release assay for HuT78 tumor lysis by PBMC from healthy volunteers, that is (a) less than or within 1-log of the EC 50  of an antibody comprising a heavy chain variable region comprising SEQ ID NO: 31, a light chain variable region comprising SEQ ID NO: 25 or 26, and an Fc region of human IgG1 isotype, and/or (b) less than 100 ng/ml, optionally between 1 and 100 ng/ml. 
     
     
         55 . The method of  claim 42 , wherein the agent is an antibody that binds specifically to a KIR3DL2 polypeptide is administered in an amount of 10 mg/kg body weight, and wherein the treatment regimen comprises:
 an induction period (or cycle) in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one administration per week, and   a treatment period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of two administrations per month.   
     
     
         56 . The method  claim 42 , wherein the agent is administered in an amount of 10 mg/kg body weight, and wherein the treatment regimen comprises:
 an induction period (or cycle) in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one administration per week, and   a treatment period in which said amount of the antibody is administered in a plurality of successive intravenous administrations at a frequency of one administration per month.   
     
     
         57 . The method of  claim 42 , wherein the individual presents pathogenic cells that express KIR3DL2 in skin. 
     
     
         58 . The method of  claim 42 , wherein the disease is a Sezary Sydrome, Mycosis fungoides or NK/T lymphoma. 
     
     
         59 . The method of  claim 42 , characterized by the absence of a step of detecting KIR3DL2-expressing malignant cells in blood prior to treatment with the agent. 
     
     
         60 . The method of  claim 42 , wherein the agent is an antibody selected from the group consisting of:
 (a) an antibody comprising a heavy chain variable region comprising SEQ ID NO: 31; and a light chain variable region comprising SEQ ID NO: 25; and   (b) an antibody comprising a heavy chain variable region comprising SEQ ID NO: 31; and a light chain variable region comprising SEQ ID NO: 26.   
     
     
         61 . The method of  claim 60 , wherein the antibody is a full length antibody comprising a heavy chain variable region (VH) fused to a human gamma 1 constant region and a light chain variable region (VL) fused to a human kappa constant region.